These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21848481)

  • 41. Candesartan cilexetil induced pustular psoriasis.
    Kawamura A; Ochiai T
    Eur J Dermatol; 2003; 13(4):406-7. PubMed ID: 12948927
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ; Schöndorfer G; Högemann AM
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract]   [Full Text] [Related]  

  • 43. A comparison of the antihypertensive effects of candesartan cilexetil and losartan in patients with mild to moderate hypertension.
    Andersson OK; Neldam S
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S63-4. PubMed ID: 9331011
    [No Abstract]   [Full Text] [Related]  

  • 44. Angiotensin receptor antagonists.
    Wong W; Howes L
    Aust Fam Physician; 2000 Jul; 29(7):653-5, 658. PubMed ID: 10914449
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors.
    Schrader J; Lüders S; Kulschewski A; Berger J; Zidek W; Treib J; Einhäupl K; Diener HC; Dominiak P;
    Stroke; 2003 Jul; 34(7):1699-703. PubMed ID: 12817109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 47. A new class of antihypertensive: angiotensin II receptor antagonists.
    McCoy R
    S D J Med; 1995 Sep; 48(9):319-20. PubMed ID: 7481726
    [No Abstract]   [Full Text] [Related]  

  • 48. Erythema multiforme associated with candesartan cilexetil.
    Ejaz AA; Walsh JS; Wasiluk A
    South Med J; 2004 Jun; 97(6):614-5. PubMed ID: 15255435
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension.
    Angeli F; Verdecchia P; Pascucci C; Poltronieri C; Reboldi G
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):379-85. PubMed ID: 23387516
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
    Leclerc J; Blais C; Rochette L; Hamel D; Guénette L; Poirier P
    Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28974512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CHARM shows improvement in NYHA functional class with candesartan.
    Cardiovasc J S Afr; 2004; 15(2):96-7. PubMed ID: 15148548
    [No Abstract]   [Full Text] [Related]  

  • 52. A look through the new therapeutic window: irbesartan.
    Waeber B; Brunner HR
    J Hypertens Suppl; 1998 Sep; 16(7):S11-6. PubMed ID: 9855026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardio classics revisited--focus on the role of candesartan.
    De Rosa ML
    Vasc Health Risk Manag; 2010 Nov; 6():1047-63. PubMed ID: 21191425
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
    Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
    Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CHARM shows benefits of Atacand for symptomatic heart failure.
    Cardiovasc J S Afr; 2003; 14(5):284. PubMed ID: 14664231
    [No Abstract]   [Full Text] [Related]  

  • 56. [AII antagonists (candesartan and irbesartan) in the treatment of cardiovascular diseases].
    Spinar J; Vítovec J
    Vnitr Lek; 2012 Oct; 58(10):755-60. PubMed ID: 23121062
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Candesartan cilexetil vs losartan.
    Bunt T
    Blood Press; 1998 Jul; 7(4):251-2. PubMed ID: 9858118
    [No Abstract]   [Full Text] [Related]  

  • 58. Successful implementation of a P&T-approved therapeutic interchange program of angiotensin II receptor blockers in a medical center in Taiwan.
    Lee YY; Hsiao P; Lin YM; Yen YH; Chen HY
    Value Health; 2012; 15(1 Suppl):S111-5. PubMed ID: 22265056
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical efficacy of a new AT1 blocker.
    Philipp T; Heemann U
    Basic Res Cardiol; 1998; 93 Suppl 2():51-3. PubMed ID: 9833163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of angiotensin II receptor antagonists in hypertension management: focus on candesartan cilexetil.
    Mancia G; Grassi G
    J Hum Hypertens; 2000 Oct; 14 Suppl 2():S3-10. PubMed ID: 11086630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.